What is the recommended valacyclovir regimen for adult genital herpes (including primary, recurrent, and suppressive therapy)?

Valacyclovir Regimens for Genital Herpes

For first-episode genital herpes, use valacyclovir 1 gram orally twice daily for 7–10 days; for recurrent episodes, use valacyclovir 500 mg twice daily for 3 days; and for suppressive therapy, use valacyclovir 500 mg or 1 gram once daily depending on recurrence frequency. 1, 2

First Clinical Episode (Primary Infection)

Valacyclovir 1 gram orally twice daily for 7–10 days is the recommended regimen for initial genital herpes, with treatment ideally initiated within 48–72 hours of symptom onset for maximum efficacy. 1, 2

• Treatment beyond 72 hours after symptom onset has not been established as effective, though clinical judgment may support initiation in severe cases. 2
• This regimen is FDA-approved and provides equivalent efficacy to acyclovir 200 mg five times daily for 10 days, with the advantage of twice-daily dosing that improves adherence. 2, 3

Recurrent Episodes (Episodic Therapy)

Valacyclovir 500 mg orally twice daily for 3 days is the preferred episodic regimen for recurrent genital herpes, offering the shortest FDA-approved treatment course. 1, 2, 4

• Alternative regimens include valacyclovir 1 gram once daily for 5 days, though the 3-day course is equally effective and more convenient. 1, 4
• Episodic therapy is most effective when initiated during the prodrome or within 1 day (ideally within 24 hours) after onset of lesions. 1, 5, 2
• Treatment initiated more than 24 hours after symptom onset has not been established as effective. 2

Alternative Episodic Regimens

If valacyclovir is unavailable or contraindicated, alternative options include:

• Acyclovir 400 mg orally three times daily for 5 days 5
• Acyclovir 800 mg orally twice daily for 5 days 5
• Famciclovir 125 mg orally twice daily for 5 days 5

Suppressive Therapy (Chronic Daily Therapy)

Valacyclovir 1 gram orally once daily is the standard suppressive regimen for patients with frequent recurrences (≥6 episodes per year), reducing recurrence frequency by ≥75%. 1, 5, 2

• For patients with ≤9 recurrences per year, valacyclovir 500 mg once daily is an acceptable alternative dose. 1, 2
• Valacyclovir is the only antiviral FDA-approved for once-daily suppressive therapy, which may improve adherence compared to twice-daily regimens. 2, 6, 7
• Safety and efficacy have been documented for up to 1 year in immunocompetent patients. 2, 7
• After 1 year of continuous suppressive therapy, consider discontinuation to reassess the patient's recurrence rate. 5

Suppressive Therapy in HIV-Infected Patients

For HIV-infected adults with CD4+ counts ≥100 cells/mm³:

• Valacyclovir 500 mg orally twice daily is the recommended suppressive regimen. 1, 2
• Safety and efficacy have been established for up to 6 months in this population. 2

Transmission Reduction

Valacyclovir 500 mg once daily is FDA-approved for reducing transmission of genital herpes to uninfected partners in heterosexual discordant couples, though safer sex practices (including condom use) must be continued. 2

• Efficacy for transmission reduction beyond 8 months has not been established. 2
• Efficacy in individuals with multiple partners or non-heterosexual couples has not been established. 2

Renal Dose Adjustments

All valacyclovir regimens require dose adjustment for creatinine clearance <50 mL/min to prevent drug accumulation and neurotoxicity. 2

Recurrent Episodes (CrCl adjustments):

• CrCl 30–49 mL/min: 500 mg every 24 hours 2
• CrCl 10–29 mL/min: 500 mg every 24 hours 2
• CrCl <10 mL/min: 500 mg every 24 hours 2

Suppressive Therapy (CrCl adjustments):

• CrCl 30–49 mL/min: No reduction for 1 gram daily; 500 mg every 48 hours for 500 mg daily regimen 2
• CrCl 10–29 mL/min: 500 mg every 24 hours 2
• CrCl <10 mL/min: 500 mg every 24 hours 2

Hemodialysis Considerations

Patients requiring hemodialysis should receive the recommended dose of valacyclovir after hemodialysis, as approximately one-third of acyclovir is removed during a 4-hour session. 2

Common Pitfalls and Caveats

• Topical acyclovir is substantially less effective than oral therapy and should not be used. 8, 5
• Do not use valacyclovir 8 grams per day, as this dose is associated with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura in immunocompromised patients. 5
• Suspect acyclovir resistance if lesions do not begin to resolve within 7–10 days of appropriate therapy; foscarnet 40 mg/kg IV every 8 hours is the alternative for proven or suspected resistance. 5
• Valacyclovir does not eradicate latent virus, does not prevent all asymptomatic viral shedding, and does not eliminate transmission risk entirely. 8, 5
• Patients should be counseled to abstain from sexual activity when lesions or prodromal symptoms are present and to use condoms during all sexual exposures with new or uninfected partners. 5

Special Populations

Pregnancy

Routine suppressive therapy is not recommended during pregnancy for recurrent genital herpes, though the safety of valacyclovir in pregnancy has not been definitively established. 5

Pediatric Patients

Valacyclovir is not FDA-approved for genital herpes in patients <18 years of age. 2

Immunocompromised Patients (Non-HIV)

Efficacy and safety have not been established in immunocompromised patients other than HIV-infected individuals with CD4+ ≥100 cells/mm³. 2